Curis Lifesciences Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Curis Lifesciences Ltd is ₹ 125 as of 18 May 15:29 . The P/E Ratio of Curis Lifesciences Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Curis Lifesciences Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The Revenue of Curis Lifesciences Ltd is ₹ 9.12 crore as of Jun '24 .The Revenue of Sanofi India Ltd is ₹ 578.9 crore as of Jun '24 . The EBITDA of Curis Lifesciences Ltd is ₹ 2.73 crore as of Jun '24 .The EBITDA of Sanofi India Ltd is ₹ 178.5 crore as of Jun '24 . The Net Profit of Curis Lifesciences Ltd is ₹ 1.2 crore as of Jun '24 .The Net Profit of Sanofi India Ltd is ₹ 136.6 crore as of Jun '24 . The dividend payout of Curis Lifesciences Ltd changed from 0 % to 0 % over 9 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 9 quarters. This represents a CAGR of -100.00% .

About Curis Lifesciences Ltd

Curis Lifesciences Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name and style of 'M/s Loreto Pharmaceutacals', pursuant to a Deed of Partnership dated 2 June, 2010.
Thereafter ' M/s Loreto Pharmaceutacals' was converted from Partnership Firm to a Private Limited Company as 'Curis Lifesciences Private Limited' and received a Certificate of Incorporation dated on March 23rd, 2016 issued by Registrar of Companies, Ahmedabad.
Subsequently, Company was converted into a Public Limited Company and the name of the Company was changed from 'Curis Lifesciences Private Limited' to 'Curis Lifesciences Limited' vide certified incorporated upon the conversion dated August 9, 2024, issued by the Central Processing Centre, Manesar. Company's business is related to manufacturing of pharmaceutical products for different markets globally as well as domestic.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Curis Lifesciences Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Curis Lifesciences Ltd or Sanofi India Ltd?

Market cap of Curis Lifesciences Ltd is 103 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Curis Lifesciences Ltd and Sanofi India Ltd?

The stock performance of Curis Lifesciences Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Curis Lifesciences Ltd and Sanofi India Ltd?

As of May 18, 2026, the Curis Lifesciences Ltd stock price is INR ₹128.2. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Curis Lifesciences Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Curis Lifesciences Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.